Surviving sepsis campaign research priorities 2023

D De Backer, CS Deutschman, J Hellman… - Critical Care …, 2024 - journals.lww.com
OBJECTIVES: To identify research priorities in the management, epidemiology, outcome,
and pathophysiology of sepsis and septic shock. DESIGN: Shortly after publication of the …

[HTML][HTML] Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases

SG Rodrigues, S van der Merwe, A Krag… - Seminars in immunology, 2024 - Elsevier
“A healthy liver stands on a healthy gut” with the gut and its barriers representing the roots
that fuel the liver and expose it to an amazing diverse mixture of gut-derived material/agents …

Review of current and new drugs for the treatment of metabolic-associated fatty liver disease

R Gish, JG Fan, Z Dossaji, J Fichez, T Laeeq… - Hepatology …, 2024 - Springer
In the past 3 decades, metabolic-associated fatty liver disease (MAFLD) has emerged as a
widespread liver condition, with its global prevalence on the rise. It ranks as a leading …

Probiotics Supplementation during Pregnancy: Can They Exert Potential Beneficial Effects against Adverse Pregnancy Outcomes beyond Gestational Diabetes …

E Poulios, E Pavlidou, SK Papadopoulou… - Biology, 2024 - mdpi.com
Simple Summary In the last few years, several clinical trials have evaluated the potential
positive effects of probiotics supplementation against several adverse pregnancy outcomes …

Probiotic consumption and hepatic steatosis: results from the NHANES 2011–2016 and Mendelian randomization study

Y Song, W Guo, J Wang, S Liu, Z Li, Y Li - Frontiers in Nutrition, 2024 - frontiersin.org
Background Recent research showed that probiotics treatment may reduce insulin
resistance, regulate lipid metabolism, raise liver enzyme levels, and ameliorate inflammation …

Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial

AS Silva-Sperb, HA Moraes, STA Barcelos… - Frontiers in …, 2024 - frontiersin.org
Background and aim Considering the increasing prevalence of non-alcoholic steatohepatitis
(NASH) and treatment gaps, this study aimed to evaluate the effect of probiotic …

Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives

S Vimalesvaran, P Vajro, A Dhawan - Hepatology International, 2024 - Springer
The historical use of the term non-alcoholic fatty liver disease (NAFLD) in obese/overweight
children has been controversial as to the appropriateness of this terminology in children …

Coprococcus protects against high-fat diet-induced nonalcoholic fatty liver disease in mice

K Lu, Y Zhou, L He, Y Li, M Shahzad… - Journal of Applied …, 2024 - academic.oup.com
Aims The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing annually,
leading to substantial medical and health burdens. Numerous studies have demonstrated …

The role of the gut-liver axis in modulating non-alcoholic fatty liver disease through dietary patterns and microecological agents

Y Fang, Z Fang, Z Li, R Yu, H Zhang, Q Wang, X Cheng… - Food Bioscience, 2023 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, closely
associated with dyslipidemia, obesity, and diabetes. The gut-liver axis (GLA) plays a pivotal …